Circulating immune complexes in cancer patients receiving goat radiolocalizing antibodies to carcinoembryonic antigen.
Circulating immune complexes in cancer patients receiving goat radiolocalizing antibodies to carcinoembryonic antigen.
复制标题
接受针对癌胚抗原的山羊放射性定位抗体的癌症患者的循环免疫复合物。
作者：
F. Primus;S. Bennett;E. Kim;F. Deland;M. Zahn;D. Goldenberg
用SephadexG-200柱层析和含有抗羊免疫球蛋白G（IgG）、抗人IgG、抗CEA或CEA的固相（SP）免疫吸附剂，研究了接受~（131）I标记羊抗癌胚抗原（CEA）抗体治疗的各种癌症患者的循环放射性和抗体免疫反应性。凝胶过滤后，超过80%的血浆放射性分布在天然IgG和排除的大分子放射性组分（样本池I）之间。天然IgG和合并液I放射性峰与SP抗山羊IgG和SP CEA的免疫反应性与进样前的放射性抗体相同。在滴度升高的患者中，循环CEA仅部分结合注射的放射性抗体，因为少于50%的放射性抗体被色谱分离为池I。来自该组患者的高达50%的池I放射性抗体与SP抗CEA结合，而其与SP抗人IgG的反应性最低。放射性抗体的清除率在具有不同量的池I放射性抗体的组之间是相似的，并且CEA放射性抗体的注射不伴随循环抗原的减少。CEA滴度较低的患者的大部分血浆放射性色谱分析为池I放射性抗体，其显示与SP抗人IgG的结合升高，但与SP抗CEA的结合未升高。通过光扫描在循环CEA-放射性抗体和抗免疫球蛋白-放射性抗体复合物的8名患者中的7名和9名患者中分别观察到肿瘤定位。因此，这些研究证明CEA以及与山羊IgG反应的人抗体可以在给予CEA放射性定位抗体注射的患者中形成免疫复合物。然而，这些复合物似乎并不能阻止肿瘤放射免疫检测。
The circulating radioactivity and antibody immunoreactivity in patients with diverse cancers who had received 131I-labeled goat antibodies to carcinoembryonic antigen (CEA) were studied by Sephadex G-200 column chromatography and with solid-phase (SP) immunoadsorbents containing anti-goat immunoglobulin G(IgG), anti-human IgG, anti-CEA, or CEA. Upon gel filtration, more than 80% of the plasma radioactivity was distributed between native IgG and an excluded macromolecular radioactive fraction (Pool I). The native IgG and Pool I radioactive peaks were immunoreactive with the SP anti-goat IgG and SP CEA to the same extent as was the radioantibody prior to injection. The circulating CEA in patients with elevated titers only partially bound the injected radioantibody since less than 50% of the latter chromatographed as Pool I. Up to 50% of the Pool I radioantibody from this group of patients was bound to the SP anti-CEA, whereas it was minimally reactive with the SP anti-human IgG. The clearance of radioantibody was similar between groups having different amounts of Pool I radioantibody, and injection of CEA radioantibody was not accompanied by a decrease in circulating antigen. Patients with lower CEA titers had the majority of the plasma radioactivity chromatographing as Pool I radioantibody which showed elevated binding to the SP anti-human IgG but not the SP anti-CEA. Tumor localization by photoscanning was observed in seven of eight and nine of nine patients who had circulating CEA-radioantibody and anti-immunoglobulin-radioantibody complexes, respectively. Thus, these studies demonstrate that CEA, as well as human antibody reactive with goat IgG, can form immune complexes in patients given injections of CEA radiolocalizing antibody. However, these complexes do not appear to prevent tumor radioimmunodetection.